AU2001274109B2 - Method of administering bisphosphonates - Google Patents

Method of administering bisphosphonates Download PDF

Info

Publication number
AU2001274109B2
AU2001274109B2 AU2001274109A AU2001274109A AU2001274109B2 AU 2001274109 B2 AU2001274109 B2 AU 2001274109B2 AU 2001274109 A AU2001274109 A AU 2001274109A AU 2001274109 A AU2001274109 A AU 2001274109A AU 2001274109 B2 AU2001274109 B2 AU 2001274109B2
Authority
AU
Australia
Prior art keywords
diphosphonic acid
ethane
hydroxy
administrations
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2001274109A
Other languages
English (en)
Other versions
AU2001274109A1 (en
Inventor
Zebulun D. Horowitz
Peter C. Richardson
Ulrich Trechsel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001274109(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001274109A1 publication Critical patent/AU2001274109A1/en
Application granted granted Critical
Publication of AU2001274109B2 publication Critical patent/AU2001274109B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001274109A 2000-06-20 2001-06-18 Method of administering bisphosphonates Expired AU2001274109B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US09/597,135 2000-06-20
US26768901P 2001-02-09 2001-02-09
US60/267,689 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (2)

Publication Number Publication Date
AU2001274109A1 AU2001274109A1 (en) 2002-03-21
AU2001274109B2 true AU2001274109B2 (en) 2004-12-23

Family

ID=26952565

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001274109A Expired AU2001274109B2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates
AU7410901A Pending AU7410901A (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU7410901A Pending AU7410901A (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Country Status (24)

Country Link
US (1) US8052987B2 (enExample)
EP (1) EP1296689B3 (enExample)
JP (2) JP4722375B2 (enExample)
KR (1) KR100864743B1 (enExample)
CN (1) CN1272013C (enExample)
AT (1) ATE304856T1 (enExample)
AU (2) AU2001274109B2 (enExample)
BR (1) BR0111806A (enExample)
CA (1) CA2410201C (enExample)
CY (2) CY1113740T1 (enExample)
CZ (1) CZ301972B6 (enExample)
DE (1) DE60113537T3 (enExample)
DK (1) DK1296689T3 (enExample)
ES (2) ES2394211T3 (enExample)
HU (1) HU228400B1 (enExample)
IL (2) IL153229A0 (enExample)
MX (1) MXPA02012682A (enExample)
NO (1) NO330459B1 (enExample)
NZ (1) NZ523086A (enExample)
PL (1) PL203087B1 (enExample)
PT (1) PT1591122E (enExample)
SK (1) SK287278B6 (enExample)
TW (1) TWI289451B (enExample)
WO (1) WO2001097788A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
IL153229A0 (en) 2000-06-20 2003-07-06 Novartis Ag Method of administering bisphosphonates
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
JP2004526747A (ja) * 2001-04-03 2004-09-02 ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン 骨移植で使用される医薬
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
ATE532523T1 (de) * 2002-09-16 2011-11-15 Novartis Pharma Gmbh Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur
TW200410701A (en) * 2002-10-15 2004-07-01 Novartis Ag Method of administering bisphosphonates
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
WO2005072746A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x受容体阻害剤
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
CA2590860C (en) 2004-12-09 2011-05-03 Merck & Co., Inc. Estrogen receptor modulators
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
CA2648594C (en) * 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20090075941A1 (en) * 2006-04-21 2009-03-19 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
JP2011519928A (ja) * 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
AR075613A1 (es) * 2009-02-25 2011-04-20 Merrion Res Iii Ltd Composicion y suministro de drogas de bifosfonato. metodo de tratamiento
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
CA2856030A1 (en) 2011-11-16 2013-05-23 Duke University Bisphosphonate compositions and methods for treating and/or reducing cardiac dysfunction
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
CA3118311A1 (en) * 2018-11-02 2020-05-07 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015155A1 (en) * 1997-09-19 1999-04-01 Leiras Oy Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
WO1999018972A1 (en) * 1997-10-10 1999-04-22 Astrazeneca Ab New improved formulation for treatment of osteoporosis
DE19853483A1 (de) * 1997-11-21 1999-05-27 Prodotti Antibiotici Spa Verwendung von Biphosphonaten zur Herstellung von pharmazeutischen Darreichungsformen zur intramuskulären Verwendung
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE114473T1 (de) 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ATE72816T1 (de) 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
NZ246456A (en) 1991-12-17 1997-03-24 Procter & Gamble Pharma Use of bone active phosphonate and a parathyroid hormone to prepare medicaments for a thirty day treatment regimen for osteoporosis
JP4481368B2 (ja) 1992-06-30 2010-06-16 味の素株式会社 骨粗鬆症の治療用のためのホスホネート類の用途
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
EP0779813A4 (en) 1994-09-09 1998-05-06 Procter & Gamble PHOSPHONATES AND PARATHORMONE AGAINST OSTEOPOROSIS
EP0779812A4 (en) 1994-09-09 1997-09-10 Procter & Gamble METHOD FOR TREATING OSTEOPOROSIS USING BONE-ACTIVE PHOSPHONATES AND PARATHORMONE
PT854724E (pt) 1995-09-29 2005-08-31 Novartis Ag Metodo de tratar a doenca navicular em cavalos
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
EP1132088A3 (en) 1997-07-22 2002-04-24 MERCK & CO. INC. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
ATE293450T1 (de) * 1999-05-21 2005-05-15 Novartis Pharma Gmbh Verwendung von biphosphonsäuren zur behandlung von angiogenese
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
IL153229A0 (en) 2000-06-20 2003-07-06 Novartis Ag Method of administering bisphosphonates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
WO1999015155A1 (en) * 1997-09-19 1999-04-01 Leiras Oy Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
WO1999018972A1 (en) * 1997-10-10 1999-04-22 Astrazeneca Ab New improved formulation for treatment of osteoporosis
DE19853483A1 (de) * 1997-11-21 1999-05-27 Prodotti Antibiotici Spa Verwendung von Biphosphonaten zur Herstellung von pharmazeutischen Darreichungsformen zur intramuskulären Verwendung

Also Published As

Publication number Publication date
EP1296689B3 (en) 2013-02-13
EP1296689A2 (en) 2003-04-02
KR20030015283A (ko) 2003-02-20
HK1072539A1 (en) 2005-09-02
NO330459B1 (no) 2011-04-18
CZ20024134A3 (cs) 2003-06-18
PL358224A1 (en) 2004-08-09
CA2410201C (en) 2010-10-26
PT1591122E (pt) 2012-12-12
WO2001097788A2 (en) 2001-12-27
AU7410901A (en) 2002-01-02
JP4722375B2 (ja) 2011-07-13
CY1113740T1 (el) 2015-08-05
ES2394211T3 (es) 2013-01-23
ES2247123T3 (es) 2006-03-01
MXPA02012682A (es) 2003-04-25
CZ301972B6 (cs) 2010-08-18
IL153229A0 (en) 2003-07-06
BR0111806A (pt) 2003-05-20
KR100864743B1 (ko) 2008-10-22
SK18082002A3 (sk) 2003-08-05
ES2247123T7 (es) 2013-03-01
SK287278B6 (sk) 2010-05-07
EP1296689B1 (en) 2005-09-21
DE60113537T2 (de) 2006-06-29
TWI289451B (en) 2007-11-11
IL153229A (en) 2007-07-24
PL203087B1 (pl) 2009-08-31
US8052987B2 (en) 2011-11-08
DE60113537D1 (de) 2006-02-02
JP2005247873A (ja) 2005-09-15
HUP0301164A3 (en) 2005-11-28
CN1620300A (zh) 2005-05-25
CY2013011I2 (el) 2015-08-05
JP2003535889A (ja) 2003-12-02
ATE304856T1 (de) 2005-10-15
DK1296689T3 (da) 2005-11-28
CN1272013C (zh) 2006-08-30
WO2001097788A3 (en) 2002-06-27
HU228400B1 (en) 2013-03-28
CA2410201A1 (en) 2001-12-27
NO20026117L (no) 2002-12-19
NZ523086A (en) 2007-07-27
DE60113537T3 (de) 2013-05-29
HUP0301164A2 (hu) 2003-08-28
JP5005188B2 (ja) 2012-08-22
CY2013011I1 (el) 2015-08-05
NO20026117D0 (no) 2002-12-19
US20030181421A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
AU2001274109B2 (en) Method of administering bisphosphonates
AU2001274109A1 (en) Method of administering bisphosphonates
US20070161603A1 (en) Method of administering bisphosphonates
CA2427161C (en) Use of bisphosphonates for pain treatment
ZA200307666B (en) Pharmaceutical uses of bisphosphonates.
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
WO2004024165A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
RU2288722C2 (ru) Способ введения бисфосфонатов
HK1072539B (en) Use of bisphosphonates in the preparation of a medicment for the treatment of conditings of abnormally increased bone turnover

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 JUL 2012 .

DA6 Amendments section 104, application for amendment withdrawn
MK14 Patent ceased section 143(a) (annual fees not paid) or expired